Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Post by reeJoeyon Mar 04, 2020 3:05pm

48 Views

Post# 30766729

Shortage in Medical Community

The US has only 10% of the required N95 maskes needed by health care workers if the coronavirus runs the way many are expecting. The improperly protected medical staff in China dropped like flies. And next need will have to be the vaccines so this doesn't happen again next year--need to be up and running ASAP so human trials can take place. Go Vaxil.

https://www.cnbc.com/2020/03/03/us-currently-has-10percent-of-face-masks-needed-for-a-full-blown-coronavirus-pandemic-hhs-official-says.html

Bullboard Posts

Apolo IV Acquisition and Marviken Ontario sign merger agreement